Our team

    Dan Geva Partner

    Download V-card

    Contact Information

    16 Abba Hillel Silver Rd.
    Ramat Gan 5250608, Israel

    Tel: 972 3 610 3121 Fax: 972 3 610 3150

    Email: dan@meitar.com

    “(A) key international player.
    Formerly of Skadden, Arps, Slate, Meagher & Flom,
    his ‘first-rate advice’ and attention to detail attract many plaudits.”
    Chambers and Partners


    “…former New York lawyer who makes his name advising emerging growth companies. Considered ‘a major league rain-maker’ and ‘a cut above the rest’.”
    Chambers and Partners

    Dan Geva is a partner in the Corporate and Securities Group. He advises Israeli and international corporations in planning and structuring complex transactions involving acquisitions, divestitures, restructurings and associated corporate finance matters. In addition, Dan has invaluable experience advising emerging growth companies in all stages of their development. Dan represents Israeli and international issuers and investment banks in a variety of financing matters, and has worked on numerous initial public offerings and other offerings registered with the US Securities and Exchange Commission, as well as offerings exempt from SEC registration pursuant to Rule 144A and Regulation S.

    Prior to joining the firm, Dan was a corporate associate at Skadden, Arps, Slate, Meagher & Flom in New York. Dan has also served as Senior Vice President and Head of Corporate Development M&A for Amdocs (NASDAQ: DOX) and as Chairman of Blades Technologies Limited.

    Representative Experience

    • Representation of M-Systems in its $1.5 billion sale to SanDisk Corporation.
    • Advice to parties to acquisition by Berkshire-Hathaway of a controlling interest in Iscar in a $4 billion transaction.
    • Representation of Actimize in its purchase by NICE Systems for approximately $300 million.
    • Representation of Ashmore in its $1.25 billion leveraged acquisition (together with Swarth Group) of ECI Telecom (NASDAQ: ECIL) and the financing arrangement for such transaction.
    • Representation of Actimize in its proposed IPO.
    • Representation of the underwriters in NICE Systems’ various ADR offerings.
    • Representation of Omrix Biopharmaceuticals in its IPO and follow-on offering.
    • Representation of Amdocs in its IPO and follow-on offerings.
    • Representation of Jacada in its IPO.
    • Representation of Optier in its $47.5 million equity investment from a syndicate of venture capital investors led by Index Ventures and Morgan Stanley.

    Selected additional publications

    • Dan is the co-author (with Mike Rimon) of the Israeli chapter of the 2008 edition of an international comparative legal guide on Mergers & Acquisitions. For the full article, click here.